SCHEMBL30376302

SCHEMBL30376302

Nc1cccc2c1CN(C1CCCNC1)C2=O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 11/20 0.62
▸ TMEM97 Q5BJF2 2/20 0.62
▸ HTR3E A5X5Y0 1/20 0.62
▸ HTR3B O95264 1/20 0.62
▸ HTR3A P46098 1/20 0.62
▸ HTR3D Q70Z44 1/20 0.62
▸ HTR3C Q8WXA8 1/20 0.62
▸ CRBN Q96SW2 2/20 0.53
▸ BRD4 O60885 1/20 0.53
▸ TNF P01375 1/20 0.53
▸ IL1B P01584 1/20 0.53
▸ IKZF1 Q13422 1/20 0.53
▸ DDB1 Q16531 1/20 0.53
▸ IKZF3 Q9UKT9 1/20 0.53
▸ PARP1 P09874 3/20 0.52
▸ HTR2C P28335 9/20 0.46
▸ HTR2A P28223 6/20 0.46
▸ MAPK1 P28482 1/20 0.45
▸ CDK4 P11802 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL660471 1.00 HTR2B (0.62) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30698072 1.00 HTR2B (0.62) HTR2BTMEM97HTR3EHTR3BHTR3A
Hydrochloric Acid SCHEMBL28593152 0.99 HTR2B (0.60) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL5667526 0.85 CRBN (0.58) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30659847 0.85 PARP1 (0.49) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30352321 0.81 PARP1 (0.47) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30459956 0.81 HTR2B (0.50) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30185022 0.81 PARP1 (0.46) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL30070147 0.81 HTR2B (0.51) HTR2BTMEM97HTR3EHTR3BHTR3A
SCHEMBL5546444 0.81 PARP1 (0.46) HTR2BTMEM97HTR3EHTR3BHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4611798-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2025-09-10 — — EP disclosed
WO-2024097905-A1 METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY CELGENE CORPORATION (US) 2024-05-10 — — WO disclosed
WO-2023051674-A1 ANTI-CD47 ANTIBODY FOR COMBINED TREATMENT OF BLOOD TUMOR 正大天晴药业集团南京顺欣制药有限公司 2023-04-06 — — WO disclosed
Send feedback